Skip to main content

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Publication ,  Journal Article
Brown, MT; Coleman, RE; Friedman, AH; Friedman, HS; McLendon, RE; Reiman, R; Felsberg, GJ; Tien, RD; Bigner, SH; Zalutsky, MR; Zhao, XG ...
Published in: Clin Cancer Res
June 1996

We aimed to determine the maximum tolerated dose (MTD) of 131I-labeled 81C6 in patients with leptomeningeal neoplasms or brain tumor resection cavities with subarachnoid communication and to identify any objective responses. 81C6 is a murine IgG monoclonal antibody that reacts with tenascin in gliomas/carcinomas but does not react with normal adult brain. 131I-labeled 81C6 delivers intrathecal (IT) radiation to these neoplasms. This study was a Phase I trial in which patients were treated with a single IT dose of 131I-labeled 81C6. Cohorts of three to six patients were treated with escalating doses of 131I (starting dose, 40 mCi; 20 mCi escalations) on 10 mg 81C6. MTD is defined as the highest dose resulting in serious toxicity in no more than two of six patients. Serious toxicity is defined as grade III/IV nonhematological toxicity or major hematological toxicity. We treated 31 patients (8 pediatric and 23 adult). Eighteen had glioblastoma multiforme. Patients were treated with 131I doses from 40 to 100 mCi. Hematological toxicity was dose limiting and correlated with the administered 131I dose. No grade III/IV nonhematological toxicities were encountered. A partial response occurred in 1 patient and disease stabilization occurred in 13 (42%) of 31 patients. Twelve patients are alive (median follow-up, > 320 days); five are progression free >409 days median posttreatment. The MTD of a single IT administration of 131I-labeled 81C6 in adults is 80 mCi 131I-labeled 81C6. The MTD in pediatric patients was not reached at 131I doses up to 40 mCi normalized for body surface area.

Duke Scholars

Published In

Clin Cancer Res

ISSN

1078-0432

Publication Date

June 1996

Volume

2

Issue

6

Start / End Page

963 / 972

Location

United States

Related Subject Headings

  • Radiotherapy Dosage
  • Radioimmunotherapy
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice
  • Meningeal Neoplasms
  • Male
  • Iodine Radioisotopes
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brown, M. T., Coleman, R. E., Friedman, A. H., Friedman, H. S., McLendon, R. E., Reiman, R., … Bigner, D. D. (1996). Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res, 2(6), 963–972.
Brown, M. T., R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, R. Reiman, G. J. Felsberg, et al. “Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.Clin Cancer Res 2, no. 6 (June 1996): 963–72.
Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, Paleologos N, Fredericks RK, Schold SC, Bigner DD. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res. 1996 Jun;2(6):963–972.

Published In

Clin Cancer Res

ISSN

1078-0432

Publication Date

June 1996

Volume

2

Issue

6

Start / End Page

963 / 972

Location

United States

Related Subject Headings

  • Radiotherapy Dosage
  • Radioimmunotherapy
  • Oncology & Carcinogenesis
  • Middle Aged
  • Mice
  • Meningeal Neoplasms
  • Male
  • Iodine Radioisotopes
  • Humans
  • Female